| Literature DB >> 34222470 |
Asmaa Rhazouani1,2,3, Halima Gamrani3, Mounir El Achaby4, Khalid Aziz5, Lhoucine Gebrati6, Md Sahab Uddin7,8, Faissal Aziz1,2.
Abstract
Nanomaterials have been widely used in many fields in the last decades, including electronics, biomedicine, cosmetics, food processing, buildings, and aeronautics. The application of these nanomaterials in the medical field could improve diagnosis, treatment, and prevention techniques. Graphene oxide (GO), an oxidized derivative of graphene, is currently used in biotechnology and medicine for cancer treatment, drug delivery, and cellular imaging. Also, GO is characterized by various physicochemical properties, including nanoscale size, high surface area, and electrical charge. However, the toxic effect of GO on living cells and organs is a limiting factor that limits its use in the medical field. Recently, numerous studies have evaluated the biocompatibility and toxicity of GO in vivo and in vitro. In general, the severity of this nanomaterial's toxic effects varies according to the administration route, the dose to be administered, the method of GO synthesis, and its physicochemical properties. This review brings together studies on the method of synthesis and structure of GO, characterization techniques, and physicochemical properties. Also, we rely on the toxicity of GO in cellular models and biological systems. Moreover, we mention the general mechanism of its toxicity.Entities:
Year: 2021 PMID: 34222470 PMCID: PMC8213470 DOI: 10.1155/2021/5518999
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Diagram of GO preparation.
Figure 2Different structures of GO.
Figure 3Atomic force microscopy image (a) and a monolayer's thickness profile of graphene oxide (b).
Figure 4SEM (a) and TEM (b) electron microscopy images of GO monolayers.
Figure 5Raman spectrum of the graphene sheet.
Figure 6Pulsed carbon-13 (1H-decoupled) NMR spectra of GO with particle sizes between 0.45 μm and 0.22 μm (a), from GO to unfractionated particles (b) and 1H →13C cross-polarized NMR spectrum, and from GO to unfractionated particles (c).
Figure 7GO FTIR specter.
Figure 8Scan range specter for the XPS analysis of GO.
Figure 9Specter range for the XRD analysis of GO.
Figure 10Thermogravimetric analyzes (TG-TGD) of GO sheets.
In vitro cytotoxicity of GO.
| Dose of GO ( | Cell line | Diameter (nm) | Time (h) | Toxic effect | Reference |
|---|---|---|---|---|---|
| 3.125-200 | Human erythrocytes | 342-765 | 24 | Hemolytic activity, ROS generation, LDH release, decreased cell viability | [ |
| 5-100 | Human fibroblast cells | 1 (height) | 24 | Dose-dependent cytotoxicity, apoptosis | [ |
| 50–100 | Mouse CT26 colon carcinoma cell | Thickness: <2 | 18 | Triggered autophagy, enhances cell death | [ |
| 100-500 | MDA-MB-231 | 156.4 | 48 | Dose-dependent cytotoxicity; DNA damage, cell cycle arrest, apoptosis | [ |
| 0–80 | HeLa cells | Size distribution: 592 ± 10.9 in PBS, 1272 ± 56.2 in FBS | 24 | Released LDH, increased MDA and ROS generation, decreased SOD, reduction of cell viability | [ |
| 20 | Macrophage cell J774A.1 | Smaller-sized GO: 50-350 | 1-24 | Size-dependent M1 induction of macrophages, proinflammatory responses | [ |
| 10-200 | Human lung epithelial A549 cells | Thickness of 0.9 | 24 | Dose-dependent oxidative stress, cell viability decreased at high concentration | [ |
| 7.8, 15.6, 31.2, 62.5, and 125 | MCF-7, HUVEC, KMBC/71 cells | 100 | 4-24 h | Significant alterations in the expression level of miR-21, miR-29a, Bax, Bcl2, and PTEN genes after treatment in all three cells | [ |
| 50 | Embryonic stem cell- (ESC-) derived cells | Thickness 1.3 | 24 h | No significant difference between the level of apoptosis of GO-treated hRPE cells and untreated hRPE controls | [ |
Figure 11Pathways of GO entry into the body.
In vivo toxicity of GO.
| Dose of GO | Animals | Diameter (nm) | Time incubation | Toxic effect | Reference |
|---|---|---|---|---|---|
| 1.0 mg/kg | Male ICR mice | Thickness of 0.9 | Intravenous injected, 24 h | Accumulated mainly in the liver and lungs | [ |
| 24 mg/kg | Male and female | Thickness of <4 | Tail vein injected, 5 days | No effect on the number of pups, sex ratio, weight, survival or growth of pups, and low male reproductive toxicity | [ |
| Series concentrations | C57BL/6 male mice | Thickness of 3.9 and 4.05 nm, size of 350 nm and 2 | Subcutaneous injection 21 days | The microsize of the GO induced much stronger inflammatory responses than the nanosize of the GO | [ |
| 0.5 or 4 mg/m3 | Sprague-Dawley rats | Thickness of 0.93 nm | Inhalation exposure, single 6 | The single inhalation exposure to GO induce minimal toxic responses in rat lungs | [ |
| 0, 1, 5, 10 mg/kg | C57BL/6 mice | — | Intratracheal instillation 0 h, 24 h, 48 h, 72 h, and 1 week | Leads to acute lung injury and chronic pulmonary fibrosis | [ |
| 4 mg/kg | Balb/c mice | Thickness of 0.94, 1.22, 4.43, and 5.66; size of 450, 25, 50, and 27 | Intraperitoneal injection 1, 7 and 30 days | Accumulated in the reticuloendothelial (RES) system including the liver and spleen over a long time | [ |
| 5, 10, 20, and 30 g kg−1 | Earthworms ( | Thickness of GO 2.1 nm | For 7, 14, 21, and 28 days | Oxidative stress and genotoxicity, resulting in lipid peroxidation, decreased lysosomal membrane stability, and DNA damage | [ |
| 5, 10, 50, and 100 mg/kg | Male Sprague-Dawley rats | — | Injection into the tail vein once a day for 7 consecutive days | Lung injury in a dose-dependent manner by inducing autophagy | [ |
| 10, 50, and 100 mg/L | Zebrafish embryos | Diameter 50-200 nm | The embryos were exposed from 6 hpf to 144 hpf in 6-well plates (20 embryos per well) | Neurodevelopmental abnormalities and altered tendency of locomotor in larval fish | [ |
Figure 12Effects of GO on organs.
Figure 13Toxicity mechanisms of GO.